Literature DB >> 29477284

Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer's disease from late-onset amyloid deposition.

Ann D Cohen1, Eric McDade2, Brad Christian3, Julie Price4, Chester Mathis5, William Klunk6, Benjamin L Handen7.   

Abstract

INTRODUCTION: The objective of this study was to evaluate amyloid β (Aβ) deposition patterns in different groups of cerebral β amyloidosis: (1) nondemented with amyloid precursor protein overproduction (Down syndrome); (2) nondemented with abnormal processing of amyloid precursor protein (preclinical autosomal dominant Alzheimer disease); (3) presumed alteration in Aβ clearance with clinical symptoms (late-onset AD); and (4) presumed alterations in Aβ clearance (preclinical AD).
METHODS: We performed whole-brain voxelwise comparison of cerebral Aβ between 23 Down syndrome, 10 preclinical autosomal dominant Alzheimer disease, 17 late-onset AD, and 16 preclinical AD subjects, using Pittsburgh Compound B-positron emission tomography.
RESULTS: We found both Down syndrome and preclinical autosomal dominant Alzheimer disease shared a distinct pattern of increased bilateral striatal and thalamic Aβ deposition compared to late-onset AD and preclinical AD.
CONCLUSION: Disorders associated with early-life alterations in amyloid precursor protein production or processing are associated with a distinct pattern of early striatal fibrillary Aβ deposition before significant cognitive impairment. A better understanding of this unique pattern could identify important mechanisms of Aβ deposition and possibly important targets for early intervention.
Copyright © 2018 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autosomal dominant Alzheimer dementia; Aβ42; Diffuse plaque; Down syndrome; Pittsburgh compound B; Striatum

Mesh:

Substances:

Year:  2018        PMID: 29477284      PMCID: PMC5994364          DOI: 10.1016/j.jalz.2018.01.002

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  35 in total

1.  Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis.

Authors:  Brian J Lopresti; William E Klunk; Chester A Mathis; Jessica A Hoge; Scott K Ziolko; Xueling Lu; Carolyn C Meltzer; Kurt Schimmel; Nicholas D Tsopelas; Steven T DeKosky; Julie C Price
Journal:  J Nucl Med       Date:  2005-12       Impact factor: 10.057

2.  Tritium-labeled (E,E)-2,5-bis(4'-hydroxy-3'-carboxystyryl)benzene as a probe for β-amyloid fibrils.

Authors:  Sergey V Matveev; Stefan Kwiatkowski; Vitaliy M Sviripa; Robert C Fazio; David S Watt; Harry LeVine
Journal:  Bioorg Med Chem Lett       Date:  2014-10-06       Impact factor: 2.823

3.  The distribution of amyloid beta protein deposition in the corpus striatum of patients with Alzheimer's disease.

Authors:  M J Brilliant; R J Elble; M Ghobrial; R G Struble
Journal:  Neuropathol Appl Neurobiol       Date:  1997-08       Impact factor: 8.090

4.  Positron emission tomography and neuropathologic estimates of fibrillar amyloid-β in a patient with Down syndrome and Alzheimer disease.

Authors:  Marwan N Sabbagh; Adam Fleisher; Kewei Chen; Joseph Rogers; Camryn Berk; Eric Reiman; Michael Pontecorvo; Mark Mintun; Daniel Skovronsky; Sandra A Jacobson; Lucia I Sue; Carolyn Liebsack; Albert S Charney; Lauren Cole; Christine Belden; Thomas G Beach
Journal:  Arch Neurol       Date:  2011-11

5.  Histopathological studies on senile plaques in brains of patients with Down's syndrome.

Authors:  Y Fukuoka; T Fujita; H Ito
Journal:  Kobe J Med Sci       Date:  1990-12

6.  Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease.

Authors:  Kangning Liu; Ingrid Solano; David Mann; Cynthia Lemere; Marc Mercken; John Q Trojanowski; Virginia M-Y Lee
Journal:  Acta Neuropathol       Date:  2006-06-01       Impact factor: 17.088

7.  Cerebral perfusion alterations and cerebral amyloid in autosomal dominant Alzheimer disease.

Authors:  Eric McDade; Albert Kim; Jeffrey James; Lei K Sheu; Dora Chieh-Hsin Kuan; Davneet Minhas; Peter J Gianaros; Snezana Ikonomovic; Oscar Lopez; Beth Snitz; Julie Price; Jim Becker; Chet Mathis; William Klunk
Journal:  Neurology       Date:  2014-07-16       Impact factor: 9.910

8.  Cognitive aging in persons with minimal amyloid-β and white matter hyperintensities.

Authors:  Robert D Nebes; Beth E Snitz; Ann D Cohen; Howard J Aizenstein; Judith A Saxton; Edythe M Halligan; Chester A Mathis; Julie C Price; M Ilyas Kamboh; Lisa A Weissfeld; William E Klunk
Journal:  Neuropsychologia       Date:  2013-08-01       Impact factor: 3.139

9.  Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study.

Authors:  Adam S Fleisher; Kewei Chen; Yakeel T Quiroz; Laura J Jakimovich; Madelyn Gutierrez Gomez; Carolyn M Langois; Jessica B S Langbaum; Napatkamon Ayutyanont; Auttawut Roontiva; Pradeep Thiyyagura; Wendy Lee; Hua Mo; Liliana Lopez; Sonia Moreno; Natalia Acosta-Baena; Margarita Giraldo; Gloria Garcia; Rebecca A Reiman; Matthew J Huentelman; Kenneth S Kosik; Pierre N Tariot; Francisco Lopera; Eric M Reiman
Journal:  Lancet Neurol       Date:  2012-11-06       Impact factor: 44.182

10.  Magnetic resonance imaging evidence for presymptomatic change in thalamus and caudate in familial Alzheimer's disease.

Authors:  Natalie S Ryan; Shiva Keihaninejad; Timothy J Shakespeare; Manja Lehmann; Sebastian J Crutch; Ian B Malone; John S Thornton; Laura Mancini; Harpreet Hyare; Tarek Yousry; Gerard R Ridgway; Hui Zhang; Marc Modat; Daniel C Alexander; Martin N Rossor; Sebastien Ourselin; Nick C Fox
Journal:  Brain       Date:  2013-03-28       Impact factor: 13.501

View more
  26 in total

Review 1.  Neuropathological correlates of amyloid PET imaging in Down syndrome.

Authors:  Eric E Abrahamson; Elizabeth Head; Ira T Lott; Benjamin L Handen; Elliott J Mufson; Bradley T Christian; William E Klunk; Milos D Ikonomovic
Journal:  Dev Neurobiol       Date:  2019-08-17       Impact factor: 3.964

2.  Frontal cortex and striatal cellular and molecular pathobiology in individuals with Down syndrome with and without dementia.

Authors:  Sylvia E Perez; Jennifer C Miguel; Bin He; Michael Malek-Ahmadi; Eric E Abrahamson; Milos D Ikonomovic; Ira Lott; Eric Doran; Melissa J Alldred; Stephen D Ginsberg; Elliott J Mufson
Journal:  Acta Neuropathol       Date:  2019-02-07       Impact factor: 17.088

3.  A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease.

Authors:  Nicolas R Barthélemy; Yan Li; Nelly Joseph-Mathurin; Brian A Gordon; Jason Hassenstab; Tammie L S Benzinger; Virginia Buckles; Anne M Fagan; Richard J Perrin; Alison M Goate; John C Morris; Celeste M Karch; Chengjie Xiong; Ricardo Allegri; Patricio Chrem Mendez; Sarah B Berman; Takeshi Ikeuchi; Hiroshi Mori; Hiroyuki Shimada; Mikio Shoji; Kazushi Suzuki; James Noble; Martin Farlow; Jasmeer Chhatwal; Neill R Graff-Radford; Stephen Salloway; Peter R Schofield; Colin L Masters; Ralph N Martins; Antoinette O'Connor; Nick C Fox; Johannes Levin; Mathias Jucker; Audrey Gabelle; Sylvain Lehmann; Chihiro Sato; Randall J Bateman; Eric McDade
Journal:  Nat Med       Date:  2020-03-11       Impact factor: 53.440

4.  Alzheimer's Disease in Down Syndrome: Progress in the Design and Conduct of Drug Prevention Trials.

Authors:  Michael S Rafii
Journal:  CNS Drugs       Date:  2020-08       Impact factor: 5.749

5.  Integrating Biomarker Outcomes into Clinical Trials for Alzheimer's Disease in Down Syndrome.

Authors:  M S Rafii; S Zaman; B L Handen
Journal:  J Prev Alzheimers Dis       Date:  2021

6.  Differentiating amyloid beta spread in autosomal dominant and sporadic Alzheimer's disease.

Authors:  Elizabeth Levitis; Jacob W Vogel; Thomas Funck; Vladimir Hachinski; Serge Gauthier; Jonathan Vöglein; Johannes Levin; Brian A Gordon; Tammie Benzinger; Yasser Iturria-Medina; Alan C Evans
Journal:  Brain Commun       Date:  2022-04-13

7.  Comparison of longitudinal Aβ in nondemented elderly and Down syndrome.

Authors:  Dana L Tudorascu; Stewart J Anderson; Davneet S Minhas; Zheming Yu; Diane Comer; Patrick Lao; Sigan Hartley; Charles M Laymon; Beth E Snitz; Brian J Lopresti; Sterling Johnson; Julie C Price; Chester A Mathis; Howard J Aizenstein; William E Klunk; Benjamin L Handen; Brad T Christian; Ann D Cohen
Journal:  Neurobiol Aging       Date:  2018-09-27       Impact factor: 4.673

8.  Regional Differences in S-Nitrosylation in the Cortex, Striatum, and Hippocampus of Juvenile Male Mice.

Authors:  Wajeha Hamoudi; Felix von Lendenfeld; Maryam Kartawy; Shira Mencer; Huda Suloh; Igor Khaliulin; Haitham Amal
Journal:  J Mol Neurosci       Date:  2021-02-16       Impact factor: 3.444

9.  Low CD4+ cell count nadir exacerbates the impacts of APOE ε4 on functional connectivity and memory in adults with HIV.

Authors:  Fan Nils Yang; Margarita Bronshteyn; Sarah A Flowers; Matthew Dawson; Princy Kumar; George William Rebeck; Raymond Scott Turner; David J Moore; Ronald J Ellis; Xiong Jiang
Journal:  AIDS       Date:  2021-04-01       Impact factor: 4.177

10.  Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study.

Authors:  Jasmeer P Chhatwal; Stephanie A Schultz; Eric McDade; Aaron P Schultz; Lei Liu; Bernard J Hanseeuw; Nelly Joseph-Mathurin; Rebecca Feldman; Colleen D Fitzpatrick; Kathryn P Sparks; Johannes Levin; Sarah B Berman; Alan E Renton; Bianca T Esposito; Maria Vitoria Fernandez; Yun Ju Sung; Jae Hong Lee; William E Klunk; Anna Hofmann; James M Noble; Neill Graff-Radford; Hiroshi Mori; Steven M Salloway; Colin L Masters; Ralph Martins; Celeste M Karch; Chengjie Xiong; Carlos Cruchaga; Richard J Perrin; Brian A Gordon; Tammie L S Benzinger; Nick C Fox; Peter R Schofield; Anne M Fagan; Alison M Goate; John C Morris; Randall J Bateman; Keith A Johnson; Reisa A Sperling
Journal:  Lancet Neurol       Date:  2022-02       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.